Examinando por Autor "Busquets Casals, David"

Mostrando 1 - 2 de 2
  • Miniatura
    Ítem
    Asymptomatic inflammatory bowel disease diagnosed during colorectal cancer population screening in Catalonia: characteristics and natural history
    (Lippincott Williams and Wilkins, 2024-12-26) Brunet Mas, Eduard; Selva, Anna; Bas Cutrina, Francesc; Brujats, Anna; Caballol Oliva, Berta; Font Marimon, Rebeca; Gómez Pastrana, Bàrbara; Gonzalez Muñosa, Carlos; Busquets Casals, David; Monfort, David; Vera, Diana Patrícia; Maristany, Elisabet; Cirera, Gemma; Torres Vicente, Gisela; Castro Poceiro, Jesús; López, Joel; González González, Laura; Màrquez Mosquera, Lucia; Gallach Montero, Marta; Esteve Comas, María; Tremosa, Gemma; Torra Alsina, Sandra; Robles Alonso, Virginia; García Iglesias, Pilar; Rodríguez Lago, Iago; Calvet Calvo, Xavier
    INTRODUCTION: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of patients with IBD with no symptoms. The aim of this study was to describe the natural history of asymptomatic IBD diagnosed through CRCSP. METHODS: An observational, longitudinal, and retrospective study was performed at 22 centers in Catalonia between January 2010 and December 2019 including patients with asymptomatic IBD detected in the CRCSP. Demographic data and IBD characteristics, evolution, and treatment were recorded. Descriptive statistics and Kaplan-Meier analysis were used for the analysis. Data were given separately for IBD, Crohn’s disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU). RESULTS: One hundred eighty-eight patients were included: 103 UC (54.8%), 60 CD (31.9%), and 25 IBDU (13.3%). Sixty-six (35.1%) were women, and the average age was 59.9 6 5.9 years. Sixty-four patients (34.0%) developed symptoms after a median follow-up of 35.6 months. Diarrhea was the most frequent symptom for CD and IBDU (25.4% and 11.5%, respectively) and blood in stools for UC (21.4%). The median time to first symptom was 11.6 months. Treatment was prescribed in 135 patients (72.2%); mesalazine was the most prescribed drug (123 patients; 65.4%). Thirteen patients (6.9%) required biological treatment. None underwent surgery. DISCUSSION: Around one-third of asymptomatic patients with IBD developed symptoms after a medium follow-up of 3 years. Only 6.9% required biological treatment, and none required surgery. Overall, prognosis of asymptomatic IBD seems better.
  • Miniatura
    Ítem
    Immigrant IBD patients in Spain are younger, have more extraintestinal manifestations and use more biologics than native patients
    (Frontiers Media, 2022-02-01) Gutiérrez Casbas, Ana ; Zapater Hernández, Pedro ; Ricart, Elena ; González-Vivó, Maria ; Gordillo Ábalos, Jordi ; Olivares, David ; Vera Mendoza, María Isabel ; Mañosa, Míriam ; Pérez Gisbert, Javier ; Aguas, Mariam ; Sánchez Rodríguez, Eugenia ; Boscá Watts, Marta Maia ; Laredo, Viviana ; Camps i Aler, Blau; Marín-Jiménez, Ignacio ; Zabana, Yamile ; Martín Arranz, María Dolores ; Muñoz Perez, Roser ; Navarro, Mercè ; Sierra Moros, Eva; Madero Velázquez, Lucía ; Vela González, Milagros ; Pérez Calle, José Lázaro ; Sainz Arnau, Empar ; Calvet Calvo, Xavier ; Arias, Lara ; Morales Alvarado, Victor Jair ; Bermejo San José, Fernando ; Fernández-Salazar, Luis Ignacio ; Van Domselaar, Manuel ; Castro Parga, María Luisa de ; Rodríguez Gutiérrez, Cristina ; Muñoz Villafranca, Carmen ; Lorente Poyatos, Rufo Humberto ; Rivero Tirado, Montserrat; Iglesias Flores, Eva ; Herreros Martinez, Belen ; Busquets Casals, David; Riera Oliver, Joan; Martínez Montiel, Pilar ; Roldon Golet, Marta ; Roncero García-Escribano, Óscar ; Hinojosa del Valle, Esther ; Sierra Ausín, Mónica ; Barrio Andrés, Jesús ; Francisco García, Ruth de ; Huguet-Malavés, Jose María ; Merino Ochoa, Olga ; Carpio López, Daniel ; Ginard Vicens, Daniel; Muñoz Núñez, José Fernando ; Piqueras, Marta ; Almela Notari, Pedro ; Argüelles Arias, Federico ; Alcaín Martínez, Guillermo ; Bujanda Fernández de Piérola, Luis ; Manceñido Marcos, Noemí ; Lucendo Villarín, Alfredo José ; Varela Trastoy, Pilar ; Rodríguez Lago, Iago ; Charola Ramos, Laura Andrea ; Sempere Robles, L. ; Sese Abizanda, Eva ; Barreiro de Acosta, Manuel ; Domènech, Eugeni ; Francés Guarinos, Rubén José
    Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and phenotypic differences. To date, no study has focused on the immigrant IBD population in Spain. Methods: Prospective, observational, multicenter study comparing cohorts of IBD patients from ENEIDA-registry who were born outside Spain with a cohort of native patients. Results: We included 13,524 patients (1,864 immigrant and 11,660 native). The immigrants were younger (45 ± 12 vs. 54 ± 16 years, p < 0.001), had been diagnosed younger (31 ± 12 vs. 36 ± 15 years, p < 0.001), and had a shorter disease duration (14 ± 7 vs. 18 ± 8 years, p < 0.001) than native patients. Family history of IBD (9 vs. 14%, p < 0.001) and smoking (30 vs. 40%, p < 0.001) were more frequent among native patients. The most prevalent ethnic groups among immigrants were Caucasian (41.5%), followed by Latin American (30.8%), Arab (18.3%), and Asian (6.7%). Extraintestinal manifestations, mainly musculoskeletal affections, were more frequent in immigrants (19 vs. 11%, p < 0.001). Use of biologics, mainly anti-TNF, was greater in immigrants (36 vs. 29%, p < 0.001). The risk of having extraintestinal manifestations [OR: 2.23 (1.92–2.58, p < 0.001)] and using biologics [OR: 1.13 (1.0–1.26, p = 0.042)] was independently associated with immigrant status in the multivariate analyses. Conclusions: Compared with native-born patients, first-generation-immigrant IBD patients in Spain were younger at disease onset and showed an increased risk of having extraintestinal manifestations and using biologics. Our study suggests a featured phenotype of immigrant IBD patients in Spain, and constitutes a new landmark in the epidemiological characterization of immigrant IBD populations in Southern Europe